{"analyses":[{"ciLowerLimit":"-9.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"22.68","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.214","paramType":"Difference (%) improvement rate of pain","paramValue":"6.64","statisticalComment":"1-sided Cochran-Mantel-Haenszel test, stratified by TTP on 1st line treatment","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.9","upperLimit":"50.5","value":"40.4"},{"groupId":"OG001","lowerLimit":"19.9","upperLimit":"47.5","value":"32.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Improvement rate of pain was defined as the number of patients with confirmed improvement of pain (based on the \"pain at its worst\" item of MDASI-MPM), divided by the number of patients evaluable for improvement of pain.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy analysis was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"Up to approx. 40 months (data cut-off: 06-Apr-2018) - Time from randomization until death from any cause.","title":"Percentage of Participants With Confirmed Improvement of Pain","type":"SECONDARY","unitOfMeasure":"percentage of participants"}